Correlations of MCP-1 −2518A>G Polymorphism and Serum Levels with Cerebral Infarction Risk: A Meta-Analysis

Abstract

This meta-analysis was performed to evaluate the relationships between the monocyte chemoattractant protein-1 (MCP-1) -2518A>G (rs1024611 A>G) polymorphism and its serum levels, and the risk of cerebral infarction. The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched for relevant articles published before October 1st, 2013 without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) or standardized mean difference (SMD) with their 95% confidence intervals (95% CIs) were calculated. Twelve case-control studies that met all the inclusion criteria were included in this meta-analysis. A total of 1272 patients with cerebral infarction and 1210 healthy control subjects were involved in this meta-analysis. Our meta-analysis results reveal that the MCP-1 -2518A>G polymorphism might increase the risk of cerebral infarction (A allele vs. G allele: OR=1.37, 95% CI: 1.18-1.60, p<0.001; GA+AA vs. GG: OR=1.33, 95% CI: 1.09-1.62, p=0.005; respectively). Furthermore, cerebral infarction patients had higher levels of serum MCP-1 than did healthy control subjects (SMD=2.96, 95% CI: 2.00-3.92, p<0.001). Statistical analysis revealed no evidence of publication bias in this meta-analysis (all p>0.05). Our findings indicate that the MCP-1 -2518A>G polymorphism and serum MCP-1 levels may contribute to the development of cerebral infarction. Thus, the MCP-1 -2518A>G polymorphism and serum MCP-1 levels could be potential biomarkers for the early detection of cerebral infarction.

<p>Exosomal Long Non-Coding RNA Expression from Serum of Patients with Acute Minor Stroke</p>

“…Acute stroke is a serious complication of cerebral vascular disease with a low occurrence of disability, which has been traditionally defined as NIHSS score with no more than 4. 1,2 According to the increasing number of stroke patients, this disease becomes a severe public health concern owing to the first leading cause of mortality and disability. 3,4 Furthermore, previous evidence have suggested that a number of severe major stroke patients suffer a stroke attack followed by initial minor stroke within the first few hours or days.…”

Monocyte chemoattractant protein-1 polymorphism interaction with spirulina immunomodulatory effects in healthy Korean elderly: A 16 week, double-blind randomized clinical trial

“…In Chinese subjects, MCP-1 -2518 A/G polymorphism was not associated with CAD risk [ 50 ]. In a previous study, we reported that subjects with A/A genotype exhibited higher MCP-1 levels than other genotypes in Korean elderly, and had higher CVD risk [ 55 ]. These results suggest that MCP-1 concentration and CVD risk vary with MCP-1 polymorphism.…”

Associations of estradiol levels and genetic polymorphisms of inflammatory genes with the risk of ischemic stroke

“…MCP-1 -2518A > G (rs1024611) and -927G > C (rs3760396) situated in the distal promoter regulatory region of the MCP-1 gene could affect the transcription of MCP-1 [24]. Two recent meta-analysis studies suggested that MCP-1 rs1024611 is associated with ischemic heart disease and ischemic stroke susceptibilities [25, 26]. Furthermore, cerebral infarction patients had higher levels of serum MCP-1 than did healthy control subjects; however, two SNPs, rs1024611 and rs3760396, were not remarkably associated with ischemic stroke, which might have been due to ethnic differences since most significant findings were observed among Caucasian populations [26].…”